

### **In the Claims**

1. – 39. (Cancelled)

40. (Previously presented) An antivenom pharmaceutical composition for treating a snakebite victim, comprising Fab fragments which bind specifically to a venom of a snake of the *Crotalus* genus and which are essentially free from contaminating Fc as determined by immunoelectrophoresis using anti-Fc antibodies, and a pharmaceutically acceptable carrier, wherein said antivenom pharmaceutical composition neutralizes the lethality of the venom of a snake of the *Crotalus* genus.

41. (Previously presented) The antivenom pharmaceutical composition of claim 40, wherein an antibody source for said Fab fragments is IgG(T).

42. (Previously presented) The antivenom pharmaceutical composition of claim 40, wherein an antibody source for said Fab fragments is polyvalent IgG(T).

43. – 49. (Cancelled)

50. (Previously presented) The antivenom pharmaceutical composition of claim 40, wherein the Fab fragments are equine.

51. – 53. (Cancelled)

54. (Withdrawn, Presently amended) A method of treating envenomation by a snake of the *Crotalus* genus comprising administering the antivenom pharmaceutical composition of any one of claims 40-42 and 50[[-53]].

55. (Withdrawn, Presently amended) The method of claim 54[[2]], wherein the antivenom pharmaceutical composition is administered intravenously.